Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Cempra’s Antibiotic Drug Close To Receiving FDA Approval



Despite the committee’s decision, analysts are not convinced that the FDA will follow their recommendation to approve solithromycin.

Share this!

November 8, 2016 | by Sarah Hand, M.Sc.

An independent advisory panel to the US Food and Drug Administration (FDA), has voted 7-6 that the regulatory agency should approve Cempra’s antibiotic drug, solithromycin. The close vote found that solithromycin’s ability to combat community-acquired bacterial pneumonia (CABP) outweighed its potential risks.

While the drug showed efficacy across multiple clinical trials, the committee was concerned about the drug’s potentially negative effects on the liver. The FDA advisory committee concluded that Cempra had failed to provide sufficient safety data on solithromycin, in order to fully assess its risks.

“We appreciate the meaningful discussion from today’s panel,” said Dr. Prabhavathi Fernandes, president and CEO of Cempra. “Their supportive view and thoughtful comments on approaches to ensuring appropriate use are consistent with Cempra’s commitment to make solithromycin available to the right patients for a five to seven day course of an oral and/or IV macrolide as monotherapy for CABP.”

Despite the committee’s decision, analysts are not convinced that the FDA will follow their recommendation to approve solithromycin. Though the FDA often does follow the guidance of the independent advisory panel, it is not obligated to do so.

“Antibiotic resistance is reaching alarming rates across the globe,” said Fernandes. “In the U.S. alone, pneumonia is the leading cause of death due to infectious disease and rates of pneumococcal resistance to current macrolides for the treatment of CABP can exceed 50 percent. We believe solithromycin has the potential to offer patients and physicians an important new treatment option and we look forward to continuing to work with the FDA as it completes its review.”

If solithromycin gains regulatory approval, it will be the first new macrolide antibiotic with both an oral and an IV formulation in more than 20 years. Cempra is also awaiting an approval decision by the European Medicines Agency (EMA).

Keywords: Antibiotic, FDA, Clinical Trials


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.